Novavax Inc Dossier - Source-backed chat

Novavax Inc

NVAXNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.94

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $10.60Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $1.7B

Enterprise Value $1.8B

Shares Outstanding 159.6M diluted

Next Earnings Date5 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Novavax is undergoing a profound business model transition from a capital-intensive, direct-commercialization COVID-19 vaccine manufacturer to a high-margin, capital-efficient licensing and partnering platform. This shift is anchored by its landmark May 2024 co-exclusive licensing agreement with Sanofi, which provided $500 million upfront and up to $700 million in potential milestones, alongside double-digit royalties on Nuvaxovid sales. By transferring commercial responsibility to Sanofi and aggressively cutting internal costs, Novavax has dramatically reduced its cash burn. Furthermore, the company is successfully monetizing its proprietary Matrix-M adjuvant platform, as evidenced by a January 2026 licensing deal with Pfizer and multiple material transfer agreements (MTAs) with top-tier oncology and infectious disease developers. Backed by a robust cash runway extending into 2028, Novavax presents a compelling, de-risked turnaround opportunity with significant non-dilutive milestone catalysts on the horizon.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets9 analysts · as of 18 Aug 2026

Low · most bearish analyst$7.00

Mean target$14.00

High · most bullish analyst$25.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$7.0020%

The bear case is driven by execution delays in the Sanofi technology transfer and regulatory hurdles that postpone the Phase 3 combination vaccine trial, pushing milestone payments into late 2027 or 2028. Additionally, underlying demand for COVID-19 vaccines continues to erode faster than anticipated, limiting the royalty streams booked by Sanofi. Shifting public health guidelines and regulatory scrutiny under new federal health leadership could also increase compliance costs and slow down partner clinical trials utilizing Matrix-M, forcing Novavax to draw heavily on its MidCap credit facility and delaying its path to profitability beyond 2028.

Base CaseCentral scenario

$14.0050%

Matches the consensus mean

The base case projects that Novavax successfully delivers on its 2026 revenue framework of $230 million to $270 million (excluding Sanofi sales/royalties) and meets its non-GAAP combined R&D and SG&A expense target of $325 million. The technology transfer to Sanofi progresses steadily, with the $75 million milestone achieved in 2027, and the Sanofi Phase 3 combination trial begins in 2027, triggering the $125 million milestone. Core operating expenses continue to decline toward the $200 million target, enabling the company to reach non-GAAP P&L profitability by 2028 as guided, supported by its existing $818 million cash and accounts receivable runway.

Bull CaseUpside scenario

$25.0030%

The bull case assumes rapid execution of the Sanofi partnership, with the Phase 3 combination vaccine trial initiating ahead of schedule, triggering the $125 million milestone in late 2026. Concurrently, Pfizer and other MTA partners quickly advance candidates utilizing the Matrix-M adjuvant into clinical trials, unlocking early development milestones. Commercial uptake of Nuvaxovid by Sanofi during the 2026-2027 vaccination season exceeds expectations, driving high-double-digit royalty streams. Under this scenario, Novavax achieves GAAP profitability by late 2027, well ahead of management's 2028 target, and establishes Matrix-M as the industry-standard adjuvant.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Transformational Sanofi partnership provides substantial non-dilutive funding ($1.2B total value) and shifts commercial execution risk to a global vaccine leader.
High-margin licensing model for the proprietary Matrix-M adjuvant platform, with active partnerships/MTAs covering over 30 unique fields of experimentation.
Aggressive cost-reduction program on track to lower annual non-GAAP combined R&D and SG&A expenses from $409 million in 2025 to $225 million in 2027, and $150-$200 million by 2028.
Strong liquidity profile with $818 million in cash and accounts receivable as of Q1 2026, providing an operational runway into 2028 without requiring dilutive equity raises.

Key Investment Risks

High reliance on Sanofi's commercial execution and sales forecasts for future royalty and milestone revenues.
Regulatory and clinical development risks associated with Sanofi's COVID-influenza combination vaccine and partners' Matrix-M pipeline candidates.
Continued secular decline in global demand for COVID-19 vaccinations, which could severely depress long-term royalty streams.
Increased regulatory and macroeconomic headwinds within the US biotechnology sector that could slow down clinical trial initiations and partner funding.

Thesis Invalidation Triggers

Termination or material negative amendment of the Sanofi licensing agreement.
Failure of Sanofi's Phase 3 COVID-influenza combination vaccine trial to meet its primary efficacy or safety endpoints.
Significant delay in the Nuvaxovid manufacturing technology transfer to Sanofi, preventing the realization of the $75 million milestone.
A material increase in core operating expenses that shortens the cash runway to well before 2028.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.